Foundation Medicine is a cancer genetic analysis corporation in the United States and a pioneer committed to gene detection and analysis. It is a professional institution for cancer gene testing recommended by oncologists and cancer patients. FoundationOne CDx (F1CDx), a comprehensive genome sequencing analysis service for all solid tumors (except for sarcoma) under the Foundation Medicine, has been approved by the FDA (US Food and Drug Administration) as the first product aimed for broad-tumor concomitant diagnosis. This world-leading genetic detection technology provides with 324 cancer-related gene variants, as well as comprehensive molecular information on tumor mutation load and microsatellite instability in a single assay. Molecular targeted drug information and clinical trial data directly correspond to FDA-approved molecular targeted therapy programs with an accuracy rate of 99% (much higher than the highest 70% accuracy of other monitoring program), helping doctors to find out molecular targeted drugs, and conduct immunotherapy for individual patients in a much more precise way. The introduction of F1CDx will establish a new standard for the individualized diagnosis and treatment of cancer in China, so that the Chinese solid tumor diagnosis and treatment would keep abreast of international standards and start a new era of efficient and precise personalized treatment.
